ReviewInternational journal of molecular sciences2017
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver.
Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 7 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Serum Insulin-Like Growth Factor 1 and the Prognosis of Patients With Advanced Liver Diseases: A Meta-Analysis.Clinical and translational gastroenterology · 2025Pooled it
- IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Hepatopulmonary syndrome secondary to metabolic associated fatty liver disease in childhood - novel treatment with growth hormone replacement therapy: a case report and systematic review of literature.Frontiers in endocrinology · 2024Pooled it
- Pooled it
- Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones.Frontiers in endocrinology · 2022Pooled it
- Markers of liver regeneration-the role of growth factors and cytokines: a systematic review.BMC surgery · 2020Pooled it
- Insulin-like growth factor-1 and non-alcoholic fatty liver disease: a systemic review and meta-analysis.Endocrine · 2019Pooled it
- Longevity-driven hepatic transcriptional programs mediate resilience to diet-induced liver injury in Ames dwarf mice.GeroScience · 2026Article
- Hemodiafiltration improves performance of 24 hour ex situ normothermic liver machine perfusion.JHEP reports : innovation in hepatology · 2026Article
- Understanding the microRNA signature associated with Reye's syndrome.Protoplasma · 2026Review
- The relationship between acromegaly and hepatic steatosis: insights from FibroScan imaging.Journal of endocrinological investigation · 2026Article
- Integrated Multi-Omics Analysis Reveals Cytokine Network Dynamics and Prognostic Signatures in Hepatitis B Virus-Associated Hepatocellular Carcinoma.Applied biochemistry and biotechnology · 2026Article
- Liver transplantation for decompensated cirrhosis of uncertain etiology in a woman with long-standing untreated panhypopituitarism: a case report.Frontiers in endocrinology · 2026Article
- Intrinsic capacity, genetic susceptibility, and the risks of metabolic dysfunction-associated steatotic liver disease and cirrhosis.International journal of surgery (London, England) · 2026Article
- Growing Pains: GH-induced Fibrosis Across Multiple Organs in bGH Mice.Endocrinology · 2025Article
- Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage.iLIVER · 2025Review
- Endocrine Disorders and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.Biomedicines · 2025Review
- Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review.European journal of translational myology · 2025Article
- Advanced Microbiome Therapeutics Accelerate MASLD Recovery by Restoring Intestinal Microbiota Equilibrium and the Gut-Liver Axis in a Mouse Model.Journal of agricultural and food chemistry · 2025Article
- Growth Hormone Replacement in Craniopharyngioma: Analysis of the Hypopituitary Control and Complications Study (HypoCCS).Journal of the Endocrine Society · 2025Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adult growth hormone deficiency (GHD) is characterized by metabolic abnormalities associated with visceral obesity, impaired quality of life, and increased mortality. Patients with adult GHD show increased prevalence of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), and growth hormone (GH) replacement therapy has been shown to improve these conditions. It has also been demonstrated that a decrease in the GH insulin-like growth factor-I (IGF-I) axis is closely associated with the progression of general NAFLD, suggesting a physiological role of these hormones for the maintenance of the liver. NASH histologically demonstrates inflammation, necrosis, and fibrosis, in addition to steatosis (and is a serious disease because it can progress to liver cirrhosis and hepatocellular carcinoma in a subset of cases). While fibrosis determines the prognosis of the patient, efficacious treatment for fibrosis is crucial; however, it has not yet been established. Recent studies have clarified the essential roles of GH and IGF-I in the liver. GH profoundly reduces visceral fat, which plays an important role in the development of NAFLD. Furthermore, GH directly reduces lipogenesis in the hepatocytes. IGF-I induces cellular senescence and inactivates hepatic stellate cells, therefore ameliorating fibrosis. IGF-I treatment has been shown to improve animal models of NASH and cirrhosis, suggesting potential clinical applications of IGF-I in these conditions. In this review, I will focus on the important roles of GH and IGF-I in the liver, their underlying mechanisms, and their potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.